Skip to main content

stock

PTGX · Protagonist Therapeutics, Inc

What Protagonist Therapeutics, Inc reports to the SEC, read from its filings.

Open in the app

Price

The live PTGX price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on PTGX.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
64,708,285 as of 2026-07-31 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
20.7%
Net
29.4%

Returns

ROE
9.9%
ROA
9.4%

Health

Current ratio
21.7x
Debt/equity
—

Deep value

NCAV
$763.15M
NCAV per share
$11.79
Price/NCAV
Locked
NNWC
$376.08M
NNWC per share
$5.81
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30$213.47M—Gross profit: unreported by this company.$158.77M$162.85M
10-Q filed 2026-08-05
2026-03-31$56.37M—Gross profit: unreported by this company.-$3.65M$3.78M
10-Q filed 2026-05-05
2025-12-31$7.44M—Gross profit: unreported by this company.-$50.35M-$44.38M
DEF 14A filed 2026-04-28
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30$4.71M—Gross profit: unreported by this company.-$46.42M-$39.34M
10-Q filed 2025-11-06
2025-06-30$5.55M—Gross profit: unreported by this company.-$42.04M-$34.77M
10-Q filed 2026-08-05
2025-03-31$28.32M—Gross profit: unreported by this company.-$19.31M-$11.65M
10-Q filed 2026-05-05
2024-12-31$170.64M—Gross profit: unreported by this company.$126.78M$131.67M
DEF 14A filed 2026-04-28
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30$4.67M—Gross profit: unreported by this company.-$41.45M-$33.21M
10-Q filed 2025-11-06
Assets
$885.54M
Equity
$841.54M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$46.02M-$158.13M-$130.15M$56.08M
2024-12-31$434.43M$252.84M$275.19M$182.80M
2023-12-31$60.00M-$93.65M-$78.96M-$70.84M
2022-12-31$26.58M-$131.37M-$127.39M-$108.93M
2021-12-31$27.36M-$125.84M-$125.55M-$108.97M
2020-12-31$28.63M-$64.52M-$66.15M-$72.95M
2019-12-31$231,000-$80.52M-$77.19M-$42.49M
2018-12-31$30.93M-$42.27M-$38.92M-$50.43M
2017-12-31$20.06M-$37.90M-$36.96M$3.21M
2016-12-31—-$32.67M-$37.18M-$30.32M

Company filings

Insiders, politicians and funds

Insider trades, last 90 days

Politician trades, last 90 days

Funds

All funds

News

Stories that named PTGX, and the market events around them.

Sign in to see this

Board

The PTGX board could not be loaded.

Retry the PTGX board

nakagai

Signals on PTGX come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the PTGX board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Protagonist Therapeutics, Inc (PTGX): SEC filings, financials and insider trades · Nakagai